Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

Por Robinson, Emily S., Matulonis, Ursula A., Ivy, Percy, Berlin, Suzanne T., Tyburski, Karin, Penson, Richard T., Humphreys, Benjamin D.
Publicado em 2010

A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cance...

Por Liu, Joyce F., Tolaney, Sara M., Birrer, Michael, Fleming, Gini F., Buss, Mary K., Dahlberg, Suzanne E., Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A.
Publicado em 2013

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Por Matulonis, Ursula A., Berlin, Suzanne, Ivy, Percy, Tyburski, Karin, Krasner, Carolyn, Zarwan, Corrine, Berkenblit, Anna, Campos, Susana, Horowitz, Neil, Cannistra, Stephen A., Lee, Hang, Lee, Julie, Roche, Maria, Hill, Margaret, Whalen, Christin, Sullivan, Laura, Tran, Chau, Humphreys, Benjamin D., Penson, Richard T.
Publicado em 2009